JP Morgan Chase
INMB icon

JP Morgan Chase’s INmune Bio INMB Stock Holding History

JP Morgan Chase’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.2K Sell
24,174
-9,071
-27% -$12.6K ﹤0.01% 6521
2026
Q1 		$37.9K Sell
33,245
-8,120
-20% -$11.6K ﹤0.01% 6307
2025
Q4 		$64.5K Sell
41,365
-16,349
-28% -$29.2K ﹤0.01% 6113
2025
Q3 		$119K Sell
57,714
-15,383
-21% -$35.2K ﹤0.01% 5798
2025
Q2 		$169K Buy
73,097
+66,700
+1,043% +$489K ﹤0.01% 5324
2025
Q1 		$50K Sell
6,397
-4,938
-44% -$39.2K ﹤0.01% 5882
2024
Q4 		$52.9K Buy
11,335
+5,461
+93% +$28.5K ﹤0.01% 5995
2024
Q3 		$31.7K Buy
5,874
+672
+13% +$4.78K ﹤0.01% 6125
2024
Q2 		$45.9K Buy
+5,202
New +$51.3K ﹤0.01% 5891
2024
Q1 		– Sell
-3,479
Closed -$39.2K – 7626
2023
Q4 		$39.2K Buy
+3,479
New +$29.2K ﹤0.01% 6069
2020
Q3 		– Sell
-3
Closed – – 5613
2020
Q2 		$0 Buy
+3
New +$15 ﹤0.01% 5522

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase's INMB Position: Q2 2026 in Review

JP Morgan Chase reduced its INmune Bio (INMB) stake by 27% in Q2 2026, selling an estimated $12.6K and leaving 24,174 shares worth $39.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6521.

JP Morgan Chase first reported a position in INMB in Q2 2020 and has held it in 11 quarters since. The position peaked at $169K in Q2 2025. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • JP Morgan Chase held 24,174 shares of INmune Bio worth $39.2K as of Q2 2026.
  • JP Morgan Chase sold 9,071 INmune Bio shares in Q2 2026, an estimated $12.6K.
  • INmune Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6521 holding.
  • JP Morgan Chase first reported a position in INmune Bio in Q2 2020 and has held it in 11 quarters since.
  • JP Morgan Chase's INmune Bio position peaked at $169K in Q2 2025.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.